Roche Holding AG (SWX:ROG)
Switzerland · Delayed Price · Currency is CHF 315.50
-4.90 (-1.53%)
Dec 17, 2025, 10:55 AM CET
Roche Holding AG Revenue
Roche Holding AG had revenue of 31.85B CHF in the half year ending June 30, 2025, with 4.03% growth. This brings the company's revenue in the last twelve months to 63.49B, up 4.80% year-over-year. In the year 2024, Roche Holding AG had annual revenue of 62.40B with 3.23% growth.
Revenue (ttm)
63.49B
Revenue Growth
+4.80%
P/S Ratio
4.31
Revenue / Employee
614.90K
Employees
103,249
Market Cap
273.76B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 62.40B | 1.95B | 3.23% |
| Dec 31, 2023 | 60.44B | -5.37B | -8.16% |
| Dec 31, 2022 | 65.81B | -36.00M | -0.05% |
| Dec 31, 2021 | 65.85B | 5.51B | 9.13% |
| Dec 31, 2020 | 60.34B | -3.41B | -5.35% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novartis AG | 44.95B |
| Sandoz Group AG | 8.42B |
| Alcon | 8.12B |
| Lonza Group AG | 7.09B |
| Galenica AG | 4.03B |
| Sonova Holding AG | 3.85B |
| Galderma Group AG | 3.73B |
| Straumann Holding AG | 2.58B |
Roche Holding AG News
- 16 hours ago - Roche in pact with Caris to discover cancer drug targets - Seeking Alpha
- 20 hours ago - Roche announces U.S. launch of next-generation cobas 6800/8800 systems and software, enhancing laboratory efficiency and testing capabilities - PRNewsWire
- 5 days ago - Roche Holding AG (RHHBY) Shareholder/Analyst Call Transcript - Seeking Alpha
- 5 days ago - Roche Holding AG (RHHBY) Shareholder/Analyst Call - Slideshow - Seeking Alpha
- 5 days ago - Roche's Oral Breast Cancer Drug Shows 30% Drop In Recurrence In Patients With Early Disease - Benzinga
- 5 days ago - Roche's Breast Cancer Drug Cuts Risk of Death by 30% in Phase III - Nasdaq
- 6 days ago - Roche Secures CE Mark Approval For Automated Mass Spectrometry Reagent Pack - Nasdaq
- 6 days ago - Roche expands automated mass spectrometry menu with antibiotics drug monitoring CE mark approval offering industry's broadest in vitro diagnostic menu - GlobeNewsWire